#ASCO25: Volastra unveils first human data of its oral KIF18A drug
Volastra Therapeutics has been bullish about KIF18A as a solid tumor drug target. And now, more than five years after launch, the company is reporting first human data from its in-house drug, VLS-1488. First findings ...
Volastra Therapeutics has been bullish about KIF18A as a solid tumor drug target.
And now, more than five years after launch, the company is reporting first human data from its in-house drug, VLS-1488.
First findings ...
